Publication | Open Access

Bumepamine, a brain-permeant benzylamine derivative of bumetanide, does not inhibit NKCC1 but is more potent to enhance phenobarbital's anti-seizure efficacy

MedicineNeurotransmitterNeuropharmacologyNeurologyNeuroscienceCentral Nervous SystemBrain-permeant Benzylamine DerivativeDopaminePharmacologyNeurochemistryAnti-seizure Efficacy